Prevention of meningococcal disease: Present and future

Reviews and Research in Medical Microbiology

Volumn 9, Issue 1, 1998, Pages 29-37

  Ferreirós, Carlos M ^a   Gómez, José A ^a   Criado, María Teresa ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Neisseria meningitidis; Vaccine

Indexed keywords

MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; POLYSACCHARIDE;

BACTERIAL INFECTION; CAUSE OF DEATH; CLINICAL TRIAL; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DISEASE CARRIER; HUMAN; IMMUNOLOGICAL MEMORY; INCIDENCE; MENINGITIS; MENINGOCOCCEMIA; MENINGOCOCCOSIS; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION;

EID: 0031974237     PISSN: 0954139X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00013542-199801000-00004     Document Type: Review

References (15)

1. Sàez-Nieto JA, Marcos C, Casal J et al. Diez años de meningitis meningococica en España (1978-1987). In: Instituto de Salud Carlos III, ed. Actividad del laboratorio de Referencia del Meningococo y comentarios epidemiologicos sobre la onda actual. Madrid: Ministerio de Sanidad y Consumo, 1988.
2. Jackson LA, Schuchat A, Reeves MW et al. Serogroup C meningococcal outbreaks in the United States. JAMA 1995; 273: 383-389.
3. Frasch C, Meningococcal vaccines. In: Cartwright K, ed. Meningococcal disease, pp. 245-283. New York: John Wiley & Sons, 1995.
4. Artenstein MS, Gold R, Zimmerly JG, Wyle FA, Branche Jr WC, Harkins C. Cutaneous reactions and antibody response to meningococcal serogroup C polysaccharide vaccines in man. J Infect Dis 1970; 121: 372-377.
5. Jennings HJ, Gamian A, Michon F et al. Unique intermolecular bactericidal epitope involving the homosialopolysaccharide capsule on the cell surface of serogroup B Neisseria meningitidis and Escherichia coli K1. J Immunol 1989; 142: 3585-3591.
6. Lepow ML, Beeler J, Randolph M et al. Reactogenicity and immunogenicity of a quadravalent combined meningococcal polysaccharide vaccine in children. J Infect Dis 1986; 154: 1033-1036.
7. Mitchell LA, Ochnio JJ, Glover C et al. Analysis of meningococcal serogroup C-specific levels in British Columbian children and adolescents. J Infect Dis 1996; 173: 1009-1013.
8. De Wals P, Dionne M, Douville-Fradet M et al. Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada. WHO Bull 1996; 74: 407-411.
9. Gorringe AR, Borrow R, Fox AJ et al. Human antibody response to meningococcal transferrin binding proteins: evidence for vaccine potential. Vaccine 1995; 13: 1207-1212.
10. Rokbi B, Mazarin V, Maitre-Wilmotte G et al. Identification of two major families of transferrin receptors among Neisseria meningitidis strains based on antigenic and genomic features. FEMS Microbiol Lett 1993; 110: 51-58.
11. Pintor M, Ferrón L, Gómez JA et al. Blocking of iron uptake from transferrin by antibodies against the transferrin binding proteins in Neisseria meningitidis. Microb Pathog 1996; 20: 127-139.
12. Lissolo L, Maitre-Wilmotte G, Dumas P et al. Evaluation of transferrin-binding protein 2 within the transferrin-binding protein complex as a potential antigen for future meningococcal vaccines. Infect Immun 1995; 63: 884-890.
13. Ala'Aldeen DAA, Borriello SP. The meningococcal transferrin-binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains. Vaccine 1996; 14: 49-53.
14. Pintor M, Ferrón L, Gómez JA et al. Blocking of iron uptake by monoclonal antibodies specific for the Neisseria meningitidis transferrin-binding protein 2. J Med Microbiol 1996; 45: 252-257.
15. Gómez JA, Agra C, Ferrón L et al. Antigenicity, cross-reactivity and surface exposure of the Neisseria meningitidis 37 kDa (Fbp). Vaccine 1996; 14: 1430-1436.